{"protocolSection": {"identificationModule": {"nctId": "NCT00317044", "orgStudyIdInfo": {"id": "D9618C00001"}, "secondaryIdInfos": [{"id": "RELAX"}], "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma", "officialTitle": "A 6-month Randomized, Double-blind, Parallel-group, Multicentre, Placebo-controlled Phase II Study to Compare Anti-asthmatic Effect and Safety of Esomeprazole (Nexium\u00ae) 40 mg Twice Daily or 40 mg Once Daily With Placebo in Adults With Asthma", "acronym": "RELAX"}, "statusModule": {"statusVerifiedDate": "2014-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-04"}, "primaryCompletionDateStruct": {"date": "2008-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-04-20", "studyFirstSubmitQcDate": "2006-04-20", "studyFirstPostDateStruct": {"date": "2006-04-24", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-04-23", "resultsFirstSubmitQcDate": "2014-05-09", "resultsFirstPostDateStruct": {"date": "2014-06-09", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-05-09", "lastUpdatePostDateStruct": {"date": "2014-06-09", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine whether treatment with esomeprazole for 6 months will improve asthma in adult patients with moderate to severe asthma and symptoms of gastroesophageal reflux disease."}, "conditionsModule": {"conditions": ["Asthma", "GERD"], "keywords": ["Moderate to severe Asthma", "Gastroesophageal Reflux Disease", "esomeprazole", "GERD"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 961, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Esomeprazole 40 mg twice daily", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Esomeprazole"]}, {"label": "Esomeprazole 40 mg once daily", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Esomeprazole"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Esomeprazole", "description": "Esomeprazole 40 mg twice daily", "armGroupLabels": ["Esomeprazole 40 mg twice daily"]}, {"type": "DRUG", "name": "Esomeprazole", "description": "Esomeprazole 40 mg once daily", "armGroupLabels": ["Esomeprazole 40 mg once daily"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo twice daily", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Change in Morning Peak Expiratory Flow (mPEF (L/Minute)) From Baseline (Mean of the Last 7 Days in the run-in Period) to Treatment Period (Mean of All Available Data During the Treatment Period).", "description": "Peak expiratory flow is defined as the maximum speed of expiration as measured with the Mini-Wright\u00ae PEF Meter. Participants must have both baseline and follow up measure to be included in analysis. Results presented as a mean of all available data during the treatment period.", "timeFrame": "Baseline to 6 months"}], "secondaryOutcomes": [{"measure": "Changes in Average Value From Baseline to Treatment Period in Evening Peak Expiratory Flow (ePEF (L/Minute))", "description": "Peak expiratory flow is defined as the maximum speed of expiration as measured with the Mini-Wright\u00ae PEF Meter. Participants must have both baseline and follow up measure to be included in analysis. No dispersion measure available.", "timeFrame": "Baseline to 6 months"}, {"measure": "Changes in Average Value From Baseline to Treatment Period in Asthma Symptom Score - Total", "description": "Participants must have both baseline and flow up measure to be included in analysis. Each morning and evening, the patient will be asked to record his/her asthma symptoms (sx) in the diary. The asthma sx scores during night- and daytime will be assessed by the patient according to the following scoring system: 0 = no asthma sx; 1 = you are aware of your asthma sx but can easily tolerate the sx; 2 = your asthma sx are causing you enough discomfort to cause problems with normal activities (or with sleep); 3 = you are unable to do your normal activities (or sleep) because of your asthma. The total symptom score is the sum of the night- and daytime scores.", "timeFrame": "Baseline to 6 months"}, {"measure": "Changes in Average Value From Baseline to Treatment Period in Number of Inhalations of Short-acting \u03b22-agonists (SABAs) - Total From Baseline to 6 Months", "description": "This is the change in the average number of inhalations from baseline to the end of the study (6 months). Participants must have both baseline and follow up measure to be included in analysis. Treatment mean calculated using the entire treatment period.", "timeFrame": "Baseline to 6 months"}, {"measure": "Changes in Average Value From Baseline to Treatment Period in Percentage of Nights With Awakening(s) Due to Asthma", "description": "Change in percentage of nights with night-time awakening(s) due to asthma from baseline to the end of the study (6 months). Participants must have both baseline and follow up measure to be included in analysis.", "timeFrame": "Baseline to 6 months"}, {"measure": "Change in Forced Expiratory Volume in 1 Second (FEV1) From Randomization to Treatment Period.", "description": "Description: Changes in forced expiratory volume in 1 second (FEV1) from randomization (Visit 3) to the treatment period considered as mean value at Visits 4-7. Participants must have both baseline and follow up measure to be included in analysis.", "timeFrame": "From randomization (Visit 3) to visit 7."}, {"measure": "Number of Patients With Severe Asthma Exacerbations.", "timeFrame": "Up to 6 months"}, {"measure": "Change in Asthma Quality of Life Questionnaire, Standardized Version (AQLQ(S)) Scores From Randomization (Visit 3) to Visit 7", "description": "The Asthma Quality of Life Questionnaire, Standardized Version (AQLQ(S))has been developed by and includes 32 questions in 4 domains: activity limitation, symptoms, emotional function, and exposure to environmental stimuli. It is used to measure the physical and emotional impact of the disease in the selected areas of life. Participants must have both baseline and follow up measure to be included in analysis.AQLQ(S) score based on a 7-point scale that ranged from 1 (worst quality of life) to 7 (best quality of life).", "timeFrame": "From randomization (Visit 3) to Visit 7"}, {"measure": "Change in Symptoms of GERD as Measured by Reflux Disease Questionnaire (RDQ) From Randomization (Visit 3) to Visit 7", "description": "The RDQ questionnaire is used to assess six GI symptoms during the previous week (a burning feeling behind the breastbone, pain behind the breastbone, a burning feeling in the centre of the stomach, pain in the centre of the stomach, an acid taste in the mouth, unpleasant movement of material upwards from the stomach). Each symptom is given a frequency score on a six-point scale (from 0=did not have to 5=daily) and an intensity score on a six-point scale (from 0=did not have to 5=severe). Three domain scores are calculated by forming averages of the frequency and intensity scores of selected symptoms (heartburn: the first two symptoms; dyspepsia: the next two symptoms; regurgitation: the last two symptoms). The overall GERD score is calculated as the average of the hearburn and dyspepsia domain scores. The GERD score can thus range from 0 to 5.", "timeFrame": "Randomization (Visit 3) to Visit 7"}, {"measure": "Number of Severe Adverse Events", "timeFrame": "Up to 6 months"}, {"measure": "Changes in Average Value From Baseline to Treatment Period in Asthma Symptom Score - Night", "description": "Participants must have both baseline and follow up measure to be included in analysis", "timeFrame": "Baseline to 6 months"}, {"measure": "Changes in Average Value From Baseline to Treatment Period in Asthma Symptom Score - Day", "description": "Participants must have both baseline and follow up measure to be included in analysis", "timeFrame": "Baseline to 6 months"}, {"measure": "Changes in Average Value From Baseline to Treatment Period in Number of Inhalations of Short-acting \u03b22-agonists (SABAs) - Night", "description": "Participants must have both baseline and follow up measure to be included in analysis", "timeFrame": "Baseline to 6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Adults with diagnosis of asthma since at least 6 months.\n* Symptoms of asthma during run-in.\n* At least 3 months history and present symptoms of 1 or more of the following: burning feeling behind breastbone, pain behind breastbone, acid taste in the mouth.\n\nExclusion Criteria:\n\n* Patients with clinically relevant abnormalities.\n* Patients with a smoking history of \u226510 pack-year.\n* Patients who have had previous surgery on the esophagus or the stomach.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "AstraZeneca Nexium Medical Science Director, MD", "affiliation": "AstraZeneca", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Research Site", "city": "Birmingham", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Research Site", "city": "Scottsdale", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 33.50921, "lon": -111.89903}}, {"facility": "Research Site", "city": "Little Rock", "state": "Arkansas", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Research Site", "city": "Fountain Valley", "state": "California", "country": "United States", "geoPoint": {"lat": 33.70918, "lon": -117.95367}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Atlanta", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Research Site", "city": "Stockbridge", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.54428, "lon": -84.23381}}, {"facility": "Research Site", "city": "Normal", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 40.5142, "lon": -88.99063}}, {"facility": "Research Site", "city": "Overland Park", "state": "Kansas", "country": "United States", "geoPoint": {"lat": 38.98223, "lon": -94.67079}}, {"facility": "Research Site", "city": "Wichita", "state": "Kansas", "country": "United States", "geoPoint": {"lat": 37.69224, "lon": -97.33754}}, {"facility": "Research Site", "city": "Mandeville", "state": "Louisiana", "country": "United States", "geoPoint": {"lat": 30.35825, "lon": -90.06563}}, {"facility": "Research Site", "city": "Wheaton", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 39.03983, "lon": -77.05526}}, {"facility": "Research Site", "city": "St. Louis", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Research Site", "city": "Papillion", "state": "Nebraska", "country": "United States", "geoPoint": {"lat": 41.15444, "lon": -96.04224}}, {"facility": "Research Site", "city": "Asheville", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.60095, "lon": -82.55402}}, {"facility": "Research Site", "city": "Cincinnati", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Research Site", "city": "Sylvania", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 41.71894, "lon": -83.71299}}, {"facility": "Research Site", "city": "Medford", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Research Site", "city": "Pittsburgh", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Research Site", "city": "Upland", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 39.85261, "lon": -75.38269}}, {"facility": "Research Site", "city": "Charleston", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "Research Site", "city": "Austin", "state": "Texas", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "Research Site", "city": "Houston", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Research Site", "city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Research Site", "city": "Kirkland", "state": "Washington", "country": "United States", "geoPoint": {"lat": 47.68149, "lon": -122.20874}}, {"facility": "Research Site", "city": "Seattle", "state": "Washington", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}, {"facility": "Research Site", "city": "Greenfield", "state": "Wisconsin", "country": "United States", "geoPoint": {"lat": 42.9614, "lon": -88.01259}}, {"facility": "Research Site", "city": "Monte Grande", "state": "Buenos Aires", "country": "Argentina"}, {"facility": "Research Site", "city": "Quilmes", "state": "Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.72904, "lon": -58.26374}}, {"facility": "Research Site", "city": "C\u00f3rdoba", "state": "C\u00f3rdoba, Argentina", "country": "Argentina", "geoPoint": {"lat": -31.4135, "lon": -64.18105}}, {"facility": "Research Site", "city": "Rosario", "state": "Santa Fe, Argentina", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Research Site", "city": "Rosario", "state": "Santa Fe", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Research Site", "city": "San Miguel De Tucum\u00e1n", "state": "Tucum\u00e1n, Argentina", "country": "Argentina", "geoPoint": {"lat": -26.82414, "lon": -65.2226}}, {"facility": "Research Site", "city": "Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Ciudad Aut\u00f3noma de Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Ciudad de Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "C\u00f3rdoba", "country": "Argentina", "geoPoint": {"lat": -31.4135, "lon": -64.18105}}, {"facility": "Research Site", "city": "Pleven", "country": "Bulgaria", "geoPoint": {"lat": 43.41667, "lon": 24.61667}}, {"facility": "Research Site", "city": "Plovdiv", "country": "Bulgaria", "geoPoint": {"lat": 42.15, "lon": 24.75}}, {"facility": "Research Site", "city": "Russe", "country": "Bulgaria", "geoPoint": {"lat": 43.85639, "lon": 25.97083}}, {"facility": "Research Site", "city": "Sofia", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Research Site", "city": "Varna", "country": "Bulgaria", "geoPoint": {"lat": 43.21667, "lon": 27.91667}}, {"facility": "Research Site", "city": "Calgary", "state": "Alberta", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "Research Site", "city": "Bay Roberts", "state": "Newfoundland and Labrador", "country": "Canada", "geoPoint": {"lat": 47.59989, "lon": -53.26478}}, {"facility": "Research Site", "city": "Holyrood", "state": "Newfoundland and Labrador", "country": "Canada", "geoPoint": {"lat": 47.38319, "lon": -53.13137}}, {"facility": "Research Site", "city": "Brampton", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.68341, "lon": -79.76633}}, {"facility": "Research Site", "city": "Hamilton", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "Research Site", "city": "Mississauga", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.5789, "lon": -79.6583}}, {"facility": "Research Site", "city": "Toronto", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Research Site", "city": "Woodstock", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.13339, "lon": -80.7497}}, {"facility": "Research Site", "city": "La Malbaie", "state": "Quebec", "country": "Canada", "geoPoint": {"lat": 47.654, "lon": -70.15268}}, {"facility": "Research Site", "city": "Montreal", "state": "Quebec", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Research Site", "city": "Quebec", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Benesov U Prahy", "country": "Czech Republic"}, {"facility": "Research Site", "city": "Beroun", "country": "Czech Republic", "geoPoint": {"lat": 49.96382, "lon": 14.072}}, {"facility": "Research Site", "city": "Cvikov", "country": "Czech Republic", "geoPoint": {"lat": 50.77668, "lon": 14.63298}}, {"facility": "Research Site", "city": "Kladno", "country": "Czech Republic", "geoPoint": {"lat": 50.14734, "lon": 14.10285}}, {"facility": "Research Site", "city": "Kolin 4", "country": "Czech Republic", "geoPoint": {"lat": 50.02806, "lon": 15.1998}}, {"facility": "Research Site", "city": "Liberec", "country": "Czech Republic", "geoPoint": {"lat": 50.76711, "lon": 15.05619}}, {"facility": "Research Site", "city": "Praha 10", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Research Site", "city": "Praha 4", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Research Site", "city": "Praha 6", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Research Site", "city": "Rokycany", "country": "Czech Republic", "geoPoint": {"lat": 49.7427, "lon": 13.59459}}, {"facility": "Research Site", "city": "Tabor", "country": "Czech Republic", "geoPoint": {"lat": 49.41441, "lon": 14.6578}}, {"facility": "Research Site", "city": "Brest", "country": "France", "geoPoint": {"lat": 48.3903, "lon": -4.48628}}, {"facility": "Research Site", "city": "Ferolles Attilly", "country": "France", "geoPoint": {"lat": 48.73184, "lon": 2.63088}}, {"facility": "Research Site", "city": "Grasse", "country": "France", "geoPoint": {"lat": 43.66667, "lon": 6.91667}}, {"facility": "Research Site", "city": "Grenoble", "country": "France", "geoPoint": {"lat": 45.16667, "lon": 5.71667}}, {"facility": "Research Site", "city": "Marseille Cedex 06", "country": "France", "geoPoint": {"lat": 43.29551, "lon": 5.38958}}, {"facility": "Research Site", "city": "Montpellier", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"facility": "Research Site", "city": "Paris Cedex", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Research Site", "city": "St Laurent Du Var", "country": "France", "geoPoint": {"lat": 43.67097, "lon": 7.17606}}, {"facility": "Research Site", "city": "Villejuif", "country": "France", "geoPoint": {"lat": 48.7939, "lon": 2.35992}}, {"facility": "Research Site", "city": "Bad W\u00f6rishofen", "country": "Germany", "geoPoint": {"lat": 48.00674, "lon": 10.59666}}, {"facility": "Research Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Research Site", "city": "Frankfurt", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Research Site", "city": "Freising", "country": "Germany", "geoPoint": {"lat": 48.40351, "lon": 11.74876}}, {"facility": "Research Site", "city": "Gelnhausen", "country": "Germany", "geoPoint": {"lat": 50.20164, "lon": 9.18742}}, {"facility": "Research Site", "city": "Gelsenkirchen", "country": "Germany", "geoPoint": {"lat": 51.50508, "lon": 7.09655}}, {"facility": "Research Site", "city": "Hamburg", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Research Site", "city": "Landsberg", "country": "Germany", "geoPoint": {"lat": 51.52698, "lon": 12.16076}}, {"facility": "Research Site", "city": "Marburg", "country": "Germany", "geoPoint": {"lat": 50.80904, "lon": 8.77069}}, {"facility": "Research Site", "city": "N\u00fcrnberg", "country": "Germany", "geoPoint": {"lat": 49.45421, "lon": 11.07752}}, {"facility": "Research Site", "city": "Potsdam", "country": "Germany", "geoPoint": {"lat": 52.39886, "lon": 13.06566}}, {"facility": "Research Site", "city": "Rodgau-dudenhofen", "country": "Germany"}, {"facility": "Research Site", "city": "Wolmirstedt", "country": "Germany", "geoPoint": {"lat": 52.24856, "lon": 11.62945}}, {"facility": "Research Site", "city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Research Site", "city": "F\u00fczesabony", "country": "Hungary", "geoPoint": {"lat": 47.75, "lon": 20.41667}}, {"facility": "Research Site", "city": "Gy\u00f6ngy\u00f6s", "country": "Hungary", "geoPoint": {"lat": 47.78257, "lon": 19.928}}, {"facility": "Research Site", "city": "Gy\u0151r", "country": "Hungary", "geoPoint": {"lat": 47.68333, "lon": 17.63512}}, {"facility": "Research Site", "city": "H\u00f3dmez\u0151v\u00e1s\u00e1rhely", "country": "Hungary", "geoPoint": {"lat": 46.41667, "lon": 20.33333}}, {"facility": "Research Site", "city": "Kaposv\u00e1r", "country": "Hungary", "geoPoint": {"lat": 46.36667, "lon": 17.8}}, {"facility": "Research Site", "city": "Mosonmagyar\u00f3v\u00e1r", "country": "Hungary", "geoPoint": {"lat": 47.86789, "lon": 17.26994}}, {"facility": "Research Site", "city": "Szombathely", "country": "Hungary", "geoPoint": {"lat": 47.23088, "lon": 16.62155}}, {"facility": "Research Site", "city": "Sz\u00e1zhalombatta", "country": "Hungary", "geoPoint": {"lat": 47.32579, "lon": 18.92141}}, {"facility": "Research Site", "city": "Cagliari", "state": "CA", "country": "Italy", "geoPoint": {"lat": 39.23054, "lon": 9.11917}}, {"facility": "Research Site", "city": "Crema", "state": "CR", "country": "Italy", "geoPoint": {"lat": 45.36264, "lon": 9.68176}}, {"facility": "Research Site", "city": "Firenze", "state": "FI", "country": "Italy", "geoPoint": {"lat": 43.77925, "lon": 11.24626}}, {"facility": "Research Site", "city": "Arenzano", "state": "GE", "country": "Italy", "geoPoint": {"lat": 44.40521, "lon": 8.68315}}, {"facility": "Research Site", "city": "Palermo", "state": "PA", "country": "Italy", "geoPoint": {"lat": 38.13205, "lon": 13.33561}}, {"facility": "Research Site", "city": "Pisa", "state": "PI", "country": "Italy", "geoPoint": {"lat": 43.70853, "lon": 10.4036}}, {"facility": "Research Site", "city": "Prato", "state": "PO", "country": "Italy", "geoPoint": {"lat": 43.8805, "lon": 11.09699}}, {"facility": "Research Site", "city": "Bussolengo", "state": "VR", "country": "Italy", "geoPoint": {"lat": 45.46903, "lon": 10.85371}}, {"facility": "Research Site", "city": "Verona", "state": "VR", "country": "Italy", "geoPoint": {"lat": 45.4299, "lon": 10.98444}}, {"facility": "Research Site", "city": "Napoli", "country": "Italy", "geoPoint": {"lat": 40.85216, "lon": 14.26811}}, {"facility": "Research Site", "city": "Roma", "country": "Italy", "geoPoint": {"lat": 41.89193, "lon": 12.51133}}, {"facility": "Research Site", "city": "Guadalajara", "state": "Jalisco", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Research Site", "city": "Zapopan", "state": "Jalisco", "country": "Mexico", "geoPoint": {"lat": 20.72356, "lon": -103.38479}}, {"facility": "Research Site", "city": "Morelia", "state": "Michoacan", "country": "Mexico", "geoPoint": {"lat": 19.70078, "lon": -101.18443}}, {"facility": "Research Site", "city": "Villahermosa", "state": "Tabasco", "country": "Mexico", "geoPoint": {"lat": 17.98689, "lon": -92.93028}}, {"facility": "Research Site", "city": "Mexico", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Research Site", "city": "Bydgoszcz", "country": "Poland", "geoPoint": {"lat": 53.1235, "lon": 18.00762}}, {"facility": "Research Site", "city": "Gdynia", "country": "Poland", "geoPoint": {"lat": 54.51889, "lon": 18.53188}}, {"facility": "Research Site", "city": "I\u0142awa", "country": "Poland", "geoPoint": {"lat": 53.59601, "lon": 19.56849}}, {"facility": "Research Site", "city": "Krak\u00f3w", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Research Site", "city": "Piekary \u015al\u0105skie", "country": "Poland", "geoPoint": {"lat": 50.38017, "lon": 18.92653}}, {"facility": "Research Site", "city": "Skar\u017cysko-Kamienna", "country": "Poland", "geoPoint": {"lat": 51.11311, "lon": 20.87162}}, {"facility": "Research Site", "city": "Strzelce Opolskie", "country": "Poland", "geoPoint": {"lat": 50.5107, "lon": 18.30056}}, {"facility": "Research Site", "city": "Tarn\u00f3w", "country": "Poland", "geoPoint": {"lat": 50.01381, "lon": 20.98698}}, {"facility": "Research Site", "city": "Zabrze", "country": "Poland", "geoPoint": {"lat": 50.32492, "lon": 18.78576}}, {"facility": "Research Site", "city": "\u0141\u00f3d\u017a", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Research Site", "city": "Amadora", "country": "Portugal", "geoPoint": {"lat": 38.75382, "lon": -9.23083}}, {"facility": "Research Site", "city": "Covilh\u00e3", "country": "Portugal", "geoPoint": {"lat": 40.28601, "lon": -7.50396}}, {"facility": "Research Site", "city": "Porto", "country": "Portugal", "geoPoint": {"lat": 41.14961, "lon": -8.61099}}, {"facility": "Research Site", "city": "Vila Nova de Gaia", "country": "Portugal", "geoPoint": {"lat": 41.13363, "lon": -8.61742}}, {"facility": "Research Site", "city": "Bratislava", "country": "Slovakia", "geoPoint": {"lat": 48.14816, "lon": 17.10674}}, {"facility": "Research Site", "city": "Kosice", "country": "Slovakia", "geoPoint": {"lat": 48.71395, "lon": 21.25808}}, {"facility": "Research Site", "city": "Nove Zamky", "country": "Slovakia", "geoPoint": {"lat": 47.98544, "lon": 18.16195}}, {"facility": "Research Site", "city": "Nov\u00e9 Z\u00e1mky", "country": "Slovakia", "geoPoint": {"lat": 47.98544, "lon": 18.16195}}, {"facility": "Research Site", "city": "Povazska Bystrica", "country": "Slovakia", "geoPoint": {"lat": 49.12153, "lon": 18.42169}}, {"facility": "Research Site", "city": "Prievidza", "country": "Slovakia", "geoPoint": {"lat": 48.77446, "lon": 18.6275}}, {"facility": "Research Site", "city": "Rimavska Sobota", "country": "Slovakia", "geoPoint": {"lat": 48.38284, "lon": 20.02239}}, {"facility": "Research Site", "city": "Tren\u010d\u00edn", "country": "Slovakia", "geoPoint": {"lat": 48.89452, "lon": 18.04436}}, {"facility": "Research Site", "city": "Basel", "state": "Basel Stadt", "country": "Switzerland", "geoPoint": {"lat": 47.55839, "lon": 7.57327}}]}, "referencesModule": {"references": [{"pmid": "20110554", "type": "DERIVED", "citation": "Kiljander TO, Junghard O, Beckman O, Lind T. Effect of esomeprazole 40 mg once or twice daily on asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2010 May 15;181(10):1042-8. doi: 10.1164/rccm.200910-1537OC. Epub 2010 Jan 28."}], "seeAlsoLinks": [{"label": "CSR-D9618C00001.pdf", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=442&filename=CSR-D9618C00001.pdf"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Four randomized patients were excluded from the ITT analysis due to missing efficacy data (2 patients), no investigational product given (1 patient), and being unblinded by the investigator (1 patient). The patient who received no investigational product was excluded from the safety analysis and is not included in the Baseline Characteristics.", "groups": [{"id": "FG000", "title": "Esomeprazole 40 mg Twice Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules twice daily"}, {"id": "FG001", "title": "Esomeprazole 40 mg Once Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules once daily"}, {"id": "FG002", "title": "Placebo", "description": "Placebo"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "320"}, {"groupId": "FG001", "numSubjects": "313"}, {"groupId": "FG002", "numSubjects": "328"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "272"}, {"groupId": "FG001", "numSubjects": "273"}, {"groupId": "FG002", "numSubjects": "283"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "48"}, {"groupId": "FG001", "numSubjects": "40"}, {"groupId": "FG002", "numSubjects": "45"}]}], "dropWithdraws": [{"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "28"}, {"groupId": "FG001", "numSubjects": "22"}, {"groupId": "FG002", "numSubjects": "20"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "4"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "12"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "3"}]}, {"type": "Multiple Reasons", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "6"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Esomeprazole 40 mg Twice Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules twice daily"}, {"id": "BG001", "title": "Esomeprazole 40 mg Once Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules once daily"}, {"id": "BG002", "title": "Placebo", "description": "Placebo"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "319"}, {"groupId": "BG001", "value": "313"}, {"groupId": "BG002", "value": "328"}, {"groupId": "BG003", "value": "960"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "44.0", "lowerLimit": "18", "upperLimit": "69"}, {"groupId": "BG001", "value": "45.0", "lowerLimit": "19", "upperLimit": "70"}, {"groupId": "BG002", "value": "45.0", "lowerLimit": "18", "upperLimit": "70"}, {"groupId": "BG003", "value": "44.667", "lowerLimit": "18", "upperLimit": "70"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "240.00"}, {"groupId": "BG001", "value": "240.00"}, {"groupId": "BG002", "value": "247.00"}, {"groupId": "BG003", "value": "727"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "79.00"}, {"groupId": "BG001", "value": "73.00"}, {"groupId": "BG002", "value": "81.00"}, {"groupId": "BG003", "value": "233"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Change in Morning Peak Expiratory Flow (mPEF (L/Minute)) From Baseline (Mean of the Last 7 Days in the run-in Period) to Treatment Period (Mean of All Available Data During the Treatment Period).", "description": "Peak expiratory flow is defined as the maximum speed of expiration as measured with the Mini-Wright\u00ae PEF Meter. Participants must have both baseline and follow up measure to be included in analysis. Results presented as a mean of all available data during the treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L/minute", "timeFrame": "Baseline to 6 months", "groups": [{"id": "OG000", "title": "Esomeprazole 40 mg Twice Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules twice daily"}, {"id": "OG001", "title": "Esomeprazole 40 mg Once Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules once daily"}, {"id": "OG002", "title": "Placebo", "description": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "316"}, {"groupId": "OG001", "value": "311"}, {"groupId": "OG002", "value": "327"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "21.1891", "spread": "2.8689", "lowerLimit": "0"}, {"groupId": "OG001", "value": "19.1847", "spread": "2.8422", "lowerLimit": "0", "upperLimit": "0"}, {"groupId": "OG002", "value": "15.6771", "spread": "2.8086", "lowerLimit": "0", "upperLimit": "0"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Average Value From Baseline to Treatment Period in Evening Peak Expiratory Flow (ePEF (L/Minute))", "description": "Peak expiratory flow is defined as the maximum speed of expiration as measured with the Mini-Wright\u00ae PEF Meter. Participants must have both baseline and follow up measure to be included in analysis. No dispersion measure available.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L/minute", "timeFrame": "Baseline to 6 months", "groups": [{"id": "OG000", "title": "Esomeprazole 40 mg Twice Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules twice daily"}, {"id": "OG001", "title": "Esomeprazole 40 mg Once Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules once daily"}, {"id": "OG002", "title": "Placebo", "description": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "316"}, {"groupId": "OG001", "value": "311"}, {"groupId": "OG002", "value": "326"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "21.88", "spread": "2.89"}, {"groupId": "OG001", "value": "18.37", "spread": "2.87"}, {"groupId": "OG002", "value": "18.55", "spread": "2.83"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Average Value From Baseline to Treatment Period in Asthma Symptom Score - Total", "description": "Participants must have both baseline and flow up measure to be included in analysis. Each morning and evening, the patient will be asked to record his/her asthma symptoms (sx) in the diary. The asthma sx scores during night- and daytime will be assessed by the patient according to the following scoring system: 0 = no asthma sx; 1 = you are aware of your asthma sx but can easily tolerate the sx; 2 = your asthma sx are causing you enough discomfort to cause problems with normal activities (or with sleep); 3 = you are unable to do your normal activities (or sleep) because of your asthma. The total symptom score is the sum of the night- and daytime scores.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline to 6 months", "groups": [{"id": "OG000", "title": "Esomeprazole 40 mg Twice Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules twice daily"}, {"id": "OG001", "title": "Esomeprazole 40 mg Once Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules once daily"}, {"id": "OG002", "title": "Placebo", "description": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "315"}, {"groupId": "OG001", "value": "311"}, {"groupId": "OG002", "value": "326"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.61", "spread": "0.05721"}, {"groupId": "OG001", "value": "-0.47", "spread": "0.05652"}, {"groupId": "OG002", "value": "-0.52", "spread": "0.05609"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Average Value From Baseline to Treatment Period in Number of Inhalations of Short-acting \u03b22-agonists (SABAs) - Total From Baseline to 6 Months", "description": "This is the change in the average number of inhalations from baseline to the end of the study (6 months). Participants must have both baseline and follow up measure to be included in analysis. Treatment mean calculated using the entire treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Inhalations", "timeFrame": "Baseline to 6 months", "groups": [{"id": "OG000", "title": "Esomeprazole 40 mg Twice Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules twice daily"}, {"id": "OG001", "title": "Esomeprazole 40 mg Once Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules once daily"}, {"id": "OG002", "title": "Placebo", "description": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "315"}, {"groupId": "OG001", "value": "311"}, {"groupId": "OG002", "value": "326"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.77", "spread": "0.10", "lowerLimit": "0", "upperLimit": "17"}, {"groupId": "OG001", "value": "-0.73", "spread": "0.10", "lowerLimit": "0", "upperLimit": "13"}, {"groupId": "OG002", "value": "-0.68", "spread": "0.10", "lowerLimit": "0", "upperLimit": "14"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Average Value From Baseline to Treatment Period in Percentage of Nights With Awakening(s) Due to Asthma", "description": "Change in percentage of nights with night-time awakening(s) due to asthma from baseline to the end of the study (6 months). Participants must have both baseline and follow up measure to be included in analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent of nights", "timeFrame": "Baseline to 6 months", "groups": [{"id": "OG000", "title": "Esomeprazole 40 mg Twice Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules twice daily"}, {"id": "OG001", "title": "Esomeprazole 40 mg Once Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules once daily"}, {"id": "OG002", "title": "Placebo", "description": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "316"}, {"groupId": "OG001", "value": "311"}, {"groupId": "OG002", "value": "327"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.238", "spread": "0.018"}, {"groupId": "OG001", "value": "-0.219", "spread": "0.018"}, {"groupId": "OG002", "value": "-0.223", "spread": "0.018"}]}]}]}, {"type": "SECONDARY", "title": "Change in Forced Expiratory Volume in 1 Second (FEV1) From Randomization to Treatment Period.", "description": "Description: Changes in forced expiratory volume in 1 second (FEV1) from randomization (Visit 3) to the treatment period considered as mean value at Visits 4-7. Participants must have both baseline and follow up measure to be included in analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "From randomization (Visit 3) to visit 7.", "groups": [{"id": "OG000", "title": "Esomeprazole 40 mg Twice Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules twice daily"}, {"id": "OG001", "title": "Esomeprazole 40 mg Once Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules once daily"}, {"id": "OG002", "title": "Placebo", "description": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "312"}, {"groupId": "OG001", "value": "306"}, {"groupId": "OG002", "value": "324"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.09", "spread": "0.02"}, {"groupId": "OG001", "value": "0.07", "spread": "0.02"}, {"groupId": "OG002", "value": "0.02", "spread": "0.02"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Severe Asthma Exacerbations.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Up to 6 months", "groups": [{"id": "OG000", "title": "Esomeprazole 40 mg Twice Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules twice daily"}, {"id": "OG001", "title": "Esomeprazole 40 mg Once Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules once daily"}, {"id": "OG002", "title": "Placebo", "description": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "318"}, {"groupId": "OG001", "value": "312"}, {"groupId": "OG002", "value": "327"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "43"}]}]}]}, {"type": "SECONDARY", "title": "Change in Asthma Quality of Life Questionnaire, Standardized Version (AQLQ(S)) Scores From Randomization (Visit 3) to Visit 7", "description": "The Asthma Quality of Life Questionnaire, Standardized Version (AQLQ(S))has been developed by and includes 32 questions in 4 domains: activity limitation, symptoms, emotional function, and exposure to environmental stimuli. It is used to measure the physical and emotional impact of the disease in the selected areas of life. Participants must have both baseline and follow up measure to be included in analysis.AQLQ(S) score based on a 7-point scale that ranged from 1 (worst quality of life) to 7 (best quality of life).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Scores on a scale", "timeFrame": "From randomization (Visit 3) to Visit 7", "groups": [{"id": "OG000", "title": "Esomeprazole 40 mg Twice Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules twice daily"}, {"id": "OG001", "title": "Esomeprazole 40 mg Once Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules once daily"}, {"id": "OG002", "title": "Placebo", "description": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "272"}, {"groupId": "OG001", "value": "275"}, {"groupId": "OG002", "value": "288"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.97", "spread": "0.07"}, {"groupId": "OG001", "value": "0.83", "spread": "0.07"}, {"groupId": "OG002", "value": "0.55", "spread": "0.07"}]}]}]}, {"type": "SECONDARY", "title": "Change in Symptoms of GERD as Measured by Reflux Disease Questionnaire (RDQ) From Randomization (Visit 3) to Visit 7", "description": "The RDQ questionnaire is used to assess six GI symptoms during the previous week (a burning feeling behind the breastbone, pain behind the breastbone, a burning feeling in the centre of the stomach, pain in the centre of the stomach, an acid taste in the mouth, unpleasant movement of material upwards from the stomach). Each symptom is given a frequency score on a six-point scale (from 0=did not have to 5=daily) and an intensity score on a six-point scale (from 0=did not have to 5=severe). Three domain scores are calculated by forming averages of the frequency and intensity scores of selected symptoms (heartburn: the first two symptoms; dyspepsia: the next two symptoms; regurgitation: the last two symptoms). The overall GERD score is calculated as the average of the hearburn and dyspepsia domain scores. The GERD score can thus range from 0 to 5.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Scores on a scale", "timeFrame": "Randomization (Visit 3) to Visit 7", "groups": [{"id": "OG000", "title": "Esomeprazole 40 mg Twice Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules twice daily"}, {"id": "OG001", "title": "Esomeprazole 40 mg Once Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules once daily"}, {"id": "OG002", "title": "Placebo", "description": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "316"}, {"groupId": "OG001", "value": "311"}, {"groupId": "OG002", "value": "327"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.95", "spread": "0.07"}, {"groupId": "OG001", "value": "-1.91", "spread": "0.07"}, {"groupId": "OG002", "value": "-1.27", "spread": "0.07"}]}]}]}, {"type": "SECONDARY", "title": "Number of Severe Adverse Events", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Events", "timeFrame": "Up to 6 months", "groups": [{"id": "OG000", "title": "Esomeprazole 40 mg Twice Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules twice daily"}, {"id": "OG001", "title": "Esomeprazole 40 mg Once Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules once daily"}, {"id": "OG002", "title": "Placebo", "description": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "316"}, {"groupId": "OG001", "value": "311"}, {"groupId": "OG002", "value": "327"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "9"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Average Value From Baseline to Treatment Period in Asthma Symptom Score - Night", "description": "Participants must have both baseline and follow up measure to be included in analysis", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline to 6 months", "groups": [{"id": "OG000", "title": "Esomeprazole 40 mg Twice Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules twice daily"}, {"id": "OG001", "title": "Esomeprazole 40 mg Once Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules once daily"}, {"id": "OG002", "title": "Placebo", "description": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "316"}, {"groupId": "OG001", "value": "311"}, {"groupId": "OG002", "value": "327"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.31", "spread": "0.03"}, {"groupId": "OG001", "value": "-0.23", "spread": "0.03"}, {"groupId": "OG002", "value": "-0.27", "spread": "0.03"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Average Value From Baseline to Treatment Period in Asthma Symptom Score - Day", "description": "Participants must have both baseline and follow up measure to be included in analysis", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline to 6 months", "groups": [{"id": "OG000", "title": "Esomeprazole 40 mg Twice Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules twice daily"}, {"id": "OG001", "title": "Esomeprazole 40 mg Once Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules once daily"}, {"id": "OG002", "title": "Placebo", "description": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "316"}, {"groupId": "OG001", "value": "311"}, {"groupId": "OG002", "value": "327"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.30", "spread": "0.03"}, {"groupId": "OG001", "value": "-0.25", "spread": "0.03"}, {"groupId": "OG002", "value": "-0.25", "spread": "0.03"}]}]}]}, {"type": "SECONDARY", "title": "Changes in Average Value From Baseline to Treatment Period in Number of Inhalations of Short-acting \u03b22-agonists (SABAs) - Night", "description": "Participants must have both baseline and follow up measure to be included in analysis", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Inhalations", "timeFrame": "Baseline to 6 months", "groups": [{"id": "OG000", "title": "Esomeprazole 40 mg Twice Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules twice daily"}, {"id": "OG001", "title": "Esomeprazole 40 mg Once Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules once daily"}, {"id": "OG002", "title": "Placebo", "description": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "316"}, {"groupId": "OG001", "value": "311"}, {"groupId": "OG002", "value": "327"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.30", "spread": "0.05"}, {"groupId": "OG001", "value": "-0.27", "spread": "0.05"}, {"groupId": "OG002", "value": "-0.29", "spread": "0.04"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Esomeprazole 40 mg Twice Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules twice daily", "seriousNumAffected": 7, "seriousNumAtRisk": 319, "otherNumAffected": 37, "otherNumAtRisk": 319}, {"id": "EG001", "title": "Esomeprazole 40 mg Once Daily", "description": "Nexium 40 mg given as esomeprazole magnesium trihydrate capsules once daily", "seriousNumAffected": 5, "seriousNumAtRisk": 313, "otherNumAffected": 44, "otherNumAtRisk": 313}, {"id": "EG002", "title": "Placebo", "description": "Placebo", "seriousNumAffected": 5, "seriousNumAtRisk": 328, "otherNumAffected": 55, "otherNumAtRisk": 328}], "seriousEvents": [{"term": "Abdominal Pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 319}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 319}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Cervical Dysplasia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 319}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Cholecystitis Acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 319}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Cholecystitis Chronic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 319}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Chronic Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 319}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 319}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 319}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Migraine With Aura", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 319}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 319}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Pulmonary Embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 319}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Renal Colic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 319}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Salmonellosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 319}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Sinus Polyp", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 319}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 328}]}, {"term": "Small Intestine Carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 319}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Tuberculosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 319}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 328}]}, {"term": "Umbilical Hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 319}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 328}]}], "otherEvents": [{"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 319}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 313}, {"groupId": "EG002", "numAffected": 18, "numAtRisk": 328}]}, {"term": "Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 26, "numAtRisk": 319}, {"groupId": "EG001", "numAffected": 28, "numAtRisk": 313}, {"groupId": "EG002", "numAffected": 37, "numAtRisk": 328}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Numbers of patients analyzed in each of the Outcome Measures varies due to the amount of qualifying data captured for the patients."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "ClinicalTrialTransparency", "organization": "AstraZeneca", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M8880", "name": "Gastroesophageal Reflux", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC06", "name": "Digestive System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000064098", "term": "Esomeprazole"}], "ancestors": [{"id": "D000000897", "term": "Anti-Ulcer Agents"}, {"id": "D000005765", "term": "Gastrointestinal Agents"}, {"id": "D000054328", "term": "Proton Pump Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M30204", "name": "Esomeprazole", "asFound": "Core", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M4188", "name": "Antacids", "relevance": "LOW"}, {"id": "M4219", "name": "Anti-Ulcer Agents", "relevance": "LOW"}, {"id": "M8881", "name": "Gastrointestinal Agents", "relevance": "LOW"}, {"id": "M27630", "name": "Proton Pump Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Gast", "name": "Gastrointestinal Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}]}}, "hasResults": true}